Publications by authors named "E Kalbacher"
Article Synopsis
- A phase 3 trial was conducted to compare the effectiveness of doxorubicin alone versus the combination of doxorubicin and trabectedin in treating advanced leiomyosarcoma.
- The trial involved 150 patients and showed that those receiving the combination therapy had a longer median overall survival (33 months) compared to those receiving doxorubicin alone (24 months), with lower death rates in the combination group.
- While the combination treatment improved progression-free survival (12 months vs. 6 months), it also led to a higher incidence of adverse events and dose reductions compared to doxorubicin alone.
This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a complete resection rate (CRR) of at least 50%. Postoperatively patients continued assigned treatment for a maximum of 2 years. Postoperative bevacizumab was optional.
View Article and Find Full Text PDFArticle Synopsis
- Recurrent cervical cancer poses serious health risks, especially after initial treatment, leading to the need for new therapy options.
- A phase 3 trial compared the effects of tisotumab vedotin to standard chemotherapy in 502 patients with recurrent or metastatic cervical cancer, focusing on overall survival.
- Results show that tisotumab vedotin significantly improved median overall survival (11.5 months vs. 9.5 months) and progression-free survival (4.2 months vs. 2.9 months), with a higher response rate compared to chemotherapy, despite both groups experiencing a high incidence of adverse events.
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers.
View Article and Find Full Text PDFBackground: Chemotherapy (CT) remains a backbone treatment of epithelial ovarian cancer (EOC) inducing persistent peripheral neuropathy (CIPN). Using a dedicated patient-reported outcome tool, this study investigated persistent CIPN and its pharmacogenetic predictors in a cohort of long-term EOC survivors.
Methods: Vivrovaire was a French multicenter cohort of patients with EOC free of disease 3 years after CT completion.